MENU
Showcases Stock ranks Forex

Pfizer Inc (PFE)
26.59  0.03 (0.11%) 03-01 16:00
Open: 26.825 Pre. Close: 26.56
High: 26.895 Low: 26.51
Volume: 39,196,138 Market Cap: 150,148(M)
Stock Technical Analysis
Overall:     
Target: Six months: 32.31
One year: 33.14
Support: Support1: 26.51
Support2: 22.06
Resistance: Resistance1: 27.66
Resistance2: 28.37
Pivot: 27.28
Moving Averages: MA(5): 26.85
MA(20): 27.27
MA(100): 29.07
MA(250): 34.08
MACD: MACD(12,26): -0.29
Signal(12,26,9): -0.24
%K %D: %K(14,3): 7.61
%D(3): 15.51
RSI: RSI(14): 37.18
52-Week: High: 42.22
Low: 25.76
Change(%): -35.4
Average Vol(K): 3-Month: 46639
10-Days: 36859
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 26.923 - 27.113 27.113 - 27.26
Low: 26.152 - 26.355 26.355 - 26.513
Close: 26.329 - 26.638 26.638 - 26.879
Price, MAs and Bollinger Bands
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.

[ PFE ] has closed above bottom band by 5.5%. Bollinger Bands are 42% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
Company profile
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Stock chart
Stock News
Fri, 01 Mar 2024
Pfizer Inc. stock rises Friday, still underperforms market - MarketWatch

Fri, 01 Mar 2024
Will Pfizer Inc (PFE) Stay at the Bottom of the Healthcare Sector? - InvestorsObserver

Thu, 29 Feb 2024
Pfizer Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Thu, 29 Feb 2024
What do the Fundamentals Predict for Pfizer Inc (PFE) Stock? - InvestorsObserver

Thu, 29 Feb 2024
Pfizer (PFE) Declined as COVID Sales Were Slower Than Expected in Q4 - Yahoo Finance

Wed, 28 Feb 2024
Pfizer Stock: A Value Trap, Not A Bargain (NYSE:PFE) - Seeking Alpha

Financial Analysis
Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  New York Stock Exchange
Sector:  Healthcare
Industry:  Drug Manufacturers—General
Shares Out. (M) 5650.00
Shares Float (M) 5640.00
% Held by Insiders 0.05
% Held by Institutions 70.09
Shares Short (K) 60190
Shares Short Prior Month (K) 57030
Stock Financials
EPS 0.370
Book Value (p.s.) 15.770
Profit Margin 3.62
Operating Margin -49.97
Return on Assets (ttm) 1.5
Return on Equity (ttm) 2.3
Qtrly Rev. Growth -41.3
Gross Profit (p.s.)
Sales Per Share 10.354
EBITDA (p.s.) 2.039
Qtrly Earnings Growth
Operating Cash Flow (M) 8700.00
Levered Free Cash Flow (M) 1020.00
Stock Valuation
PE Ratio 71.86
PEG Ratio -12.23
Price to Book value 1.69
Price to Sales 2.57
Price to Cash Flow 17.27
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android